Mayukh Dealtrade Ltd

Tavexia Lifecare Limited, formerly Sattva Sukun Lifecare Limited, has announced a rebranding and strategic expansion into high-growth verticals including APIs, finished formulations, CDMO/CRAMS, and nutraceuticals. The company has also acquired a 60% controlling stake in Meyonex Pharmaceuticals Limited for ₹67.19 Crore (2,09,97,180 shares at ₹32 per share). This acquisition provides immediate operational capabilities and significant synergies. Tavexia plans strategic fund-raising to support its growth roadmap in the resilient pharmaceutical and lifecare sector, leveraging global supply-chain diversification and increasing demand for specialized services.

Tavexia Lifecare Limited's Board of Directors has approved the proposed acquisition of up to 60% of the equity share capital of Meyonex Pharmaceuticals Limited. The acquisition will be done through a subscription of fresh equity shares at an issue price of ₹32 per share, amounting to a total investment of ₹67,19,09,760 (₹671.91 Crore). This strategic move aims to increase Tavexia Lifecare's stake in Meyonex Pharmaceuticals to 60%, with existing shareholders retaining 40%. The Board also reviewed and approved the Valuation and Due Diligence reports related to this acquisition. The funding for this acquisition will be entirely in cash. Further, the Board considered the fund-raising requirements to finance this proposed investment.

Tavexia Lifecare Limited's Board of Directors has approved the proposed acquisition of up to 60% of Meyonex Pharmaceuticals Limited's equity share capital. The acquisition will be executed through a subscription of fresh equity shares by Tavexia Lifecare, at an issue price of ₹32 per share. This will result in Tavexia Lifecare holding 60% of Meyonex's post-allotment equity share capital, with existing shareholders retaining 40%. The total investment for this acquisition amounts to ₹67,19,09,760 (₹671.91 Crore), to be paid entirely in cash. The Board also approved the Valuation and Due Diligence Report for the transaction. The company is also considering fund-raising options to finance this acquisition.

Tavexia Lifecare Ltd has scheduled a Board of Directors meeting for October 7, 2026, to further discuss and approve the proposed acquisition of up to 60% equity share capital in Meyonex Pharmaceuticals Limited. This follows a previous board approval on September 7, 2026, which authorized preliminary due diligence and negotiations. The meeting will also address the trading window closure for designated persons and their relatives, effective from September 30, 2026, until 48 hours after the board meeting for un-audited financial results.

Roshan Dealmark Private Limited has disclosed the sale of 2,50,000 equity shares in Tavexia Lifecare Limited on September 28, 2026, via an on-market transaction. This sale represents a 0.065% stake in the company. Following the transaction, Roshan Dealmark's holding in Tavexia Lifecare has reduced from 3.713% to 3.647%. The total equity share capital of Tavexia Lifecare Limited remains unchanged at Rs 38,36,01,248.

Tavexia Lifecare Ltd has announced the closure of its trading window from October 1, 2026, to facilitate the declaration of un-audited financial results for the quarter and half-year ended September 30, 2026. The window will reopen 48 hours after the announcement of these results. This closure applies to directors, promoters, designated persons, and their immediate relatives, in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015.

Roshan Dealmark Private Limited has disclosed the sale of 7,00,000 equity shares in Tavexia Lifecare Ltd (formerly Sattva Sukun Lifecare Limited) on September 25, 2026, through an on-market transaction. This sale represents a 0.182% stake in the company. Following the transaction, Roshan Dealmark's holding in Tavexia Lifecare has reduced from 3.895% to 3.713% of the total equity share capital. The total diluted share capital of Tavexia Lifecare remains unchanged at 38,36,01,248 equity shares.

Roshan Dealmark Private Limited, a promoter group entity of Tavexia Lifecare Ltd, has sold 2,00,000 equity shares, representing 0.052% of the total capital, through an on-market transaction on September 24, 2026. Following this sale, Roshan Dealmark's holding in Tavexia Lifecare has reduced from 3.947% to 3.895%. The total paid-up capital of the company remains unchanged at Rs 38,36,01,248.

Roshan Dealmark Private Limited has sold 4,00,000 equity shares of Tavexia Lifecare Ltd (formerly Sattva Sukun Lifecare Limited) through an on-market transaction on September 23, 2026. This sale represents a 0.104% stake in the company. Following the transaction, Roshan Dealmark's holding in Tavexia Lifecare has reduced from 4.051% to 3.947%. The total number of shares held by Roshan Dealmark before the sale was 1,55,40,794, and after the sale, it stands at 1,51,40,794. The transaction was conducted on the Bombay Stock Exchange.

Roshan Dealmark Private Limited, a promoter group entity of Tavexia Lifecare Ltd, has disposed of 9,07,105 equity shares, representing 0.237% of the total share capital. The transaction occurred on-market on September 21, 2026. Following the disposal, Roshan Dealmark's shareholding in Tavexia Lifecare has reduced from 4.288% to 4.051%. This disclosure is made in compliance with SEBI's Substantial Acquisition of Shares & Takeovers Regulations, 2011, and Prohibition of Insider Trading Regulations, 2015.